Background: Retinoids are under intensive study for the treatment and prevention of cancer. Substantial dose-related toxicities of retinoids are a major obstacle to this work. In a recent retrospective analysis of combined 13-cis-retinoic acid (13cRA) and alpha-tocopherol (AT) in myelodysplasia, 13cRA toxicity was reduced significantly and 13cRA activity was enhanced. These results suggested the need for prospective testing of this new combination. This trial tested the hypotheses that AT can reduce toxicity of high-dose 13cRA and does not interfere with 13cRA absorption/activity as reflected by reduced 13cRA serum levels.
Introduction
Various analogues of retinoic acid (synthetic and natural retinoids) are under active investigation for cancer therapy (against hematologic and solid tumors) and prevention [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . In the broad sense of prevention, retinoids are being investigated aggressively in several sites for a) their adjuvant effects in preventing second primary tumors after surgery and/or radiation and for b) their effects in reversing premalignant lesions.
A major obstacle to this research, especially in the adjuvant and chemoprevention settings, are the substantial clinical toxicities associated with retinoid administration. Skin dryness/peeling and cheilitis; conjunctivitis and headaches; hypertriglyceridemia and liver function abnormalities -all these side effects can require dose reductions or discontinuation of retinoid within several weeks or months of beginning treatment [1, 2] . These effects also adversely affect compliance with retinoid therapy, thus further limiting retinoid trials. Retinoid toxicity is a serious problem that must be remedied as retinoids enter the arena of the long-term, large-scale prevention trials involving relatively healthy subjects [3] .
Nutritional interactions between vitamins A and E in animal models are well known [20] . In these models, a high-vitamin-A diet causes reductions in tissue and plas-ma levels of AT, and vitamin E supplementation can alleviate or prevent symptoms of hypervitaminosis A [21, 22] . In animal models, combined retinoid and AT has significantly more chemopreventive activity in oral carcinogenesis than does either agent alone. AT recently has been shown to have single-agent activity in patients with oral leukoplakia [23] .
In a study of the retinoid 13-cis-retinoic acid (13cRA) in myelodysplasia, Besa et al. [18] made the incidental observation that patients taking over-the-counter alphatocopherol (AT) supplementation appeared to have less retinoid toxicity than did those not taking AT. Subsequently these investigators added AT to the 13cRA study regimen and compared this combination with their historical results of 13cRA alone [19] . Compared with 13cRA alone, AT (800 IU/day) combined with 13cRA significantly reduced mucocutaneous toxicity, liver function abnormalities and hypertriglyceridemia and increased the overall activity.
Confirmation of the Besa results could have a major effect on retinoid research. The ability of AT to significantly or substantially reduce retinoid toxicity would allow higher, potentially more effective drug doses and so improve compliance within both short-and long-term therapeutic and chemopreventive retinoid trials. Therefore, we conducted a phase I trial of 13cRA (100 mg/m 2 / day) plus AT (beginning at 800 IU/day, escalating monthly until 2,000 IU/day) to test the hypothesis that AT reduces 13cRA toxicity. Our choice of this high dose of 13cRA was based on its record of established chemopreventive activity in the head and neck and skin [5] [6] [7] [8] . We also conducted pharmacokinetic studies to test the hypothesis that AT reduction of 13cRA toxicity does not involve lowering serum levels of 13cRA.
Treatment
This was a phase I, single-arm trial of combined high-dose 13cRA and AT. Patients received 13cRA (provided by Hoffmann LaRoche, Inc., Nutley, NJ, USA) in a fixed daily oral dose of 100 mg/m 2 (rounded to the nearest 10 mg) to be taken with meals and without interruption. To be taken simultaneously with 13cRA, AT (provided by Hoffmann La Roche, Inc.) was started at 800 IU/day and was scheduled for intrapatient escalation up to 2,000 IU/day. Patients were continued on therapy until progression or unacceptable toxicity. Patients who achieve a complete remission were to continue on therapy for 12 months. Patients with minor response or no change in disease status were to continue until disease progression.
After study entry, patients were evaluated every four weeks, each 4-week period being considered one course of therapy. We monitored toxicity and compliance through patients' self-report diaries and their regular monthly clime visits. Patients found to have ^ grade 2 toxicity were monitored weekly through telephone calls from our research nurse. Depending on observed toxicity, the AT dose was scheduled to be increased every four weeks by increments of 400 IU/day (up to the maximum of 2,000 IU/day). In cases of grade 1-2 mucocutaneous toxicities, AT was escalated regularly every four weeks as 13cRA continued at the fixed level. In cases of grade 3 toxicity: AT was maintained at the previous level (not escalated) and 13cRA was suspended until toxicity resolved to $ grade 1; then 13cRA was resumed and the AT dose was escalated to the next level. In cases of grade 4 toxicity: both agents were suspended until toxicity resolved to < grade 1; then 13cRA resumed at 80% (80 mgW/day) of the starting dose and AT was resumed with an escalation to the next level; if this modified 13cRA dose was tolerated for four weeks, then it was increased to the starting level of 100 mg/m 2 /day. Maximum doses of 13cRA and AT were 100 mg/m 2 /day and 2,000 IU/day, respectively
Triglyceride levels were monitored initially at baseline and subsequently every 4 weeks. Hypertriglyceridemia was graded according to a grading system devised at M.D. Anderson Cancer Center which incorporates the NCI Common Toxicity Criteria [24] . Dose modifications of 13cRA and AT in conjunction with grades 1, 2, 3 and 4 hypertriglyceridemia were similar to those attending the various grades of mucocutaneous toxicity (described in the preceding paragraph). In cases of > grade 2 hypertriglyceridemia, lopid (600 mg p.o. twice daily) was begun in conjunction with 13cRA plus ATand continued throughout the study.
Patients and methods

Patient eligibility
To be eligible, patients had to have histologically ascertained recurrent or metastatic cancer, or be at high risk of developing recurrent disease in these sites; or have premalignant oral or bronchial lesions. These patients may have received one or more prior chemotherapy treatments. Other eligibility criteria included the ability to ingest oral medication; a Zubrod performance status of < 2; adequate marrow function (absolute granulocyte count > 1,500 cells/ul and platelets > 100,000 cells/ul); adequate hepatic function (SGOT $ 4 x the upper limit of normal); adequate coagulation function (prothrombin time of 10-124 seconds and partial prothrombin time of 24.3-36.3 seconds); and adequate lipid metabolism (cholesterol $ 280 mg/dl and triglyceride < 160 mg/dl [males], $ 135 mg/dl [females]).
Exclusion criteria included currently receiving immunotherapy, hormonal therapy, radiotherapy or other chemotherapy; women of childbearing potential; retinoid therapy within the preceding three months; chronic oral anti-coagulant therapy; and eligibility for protocol(s) of higher priority.
All patients gave written informed consent according to the policy of The Institutional Protocol Review Board of the University of Texas M.D. Anderson Cancer Center (UTMDACQ.
Pharmacokinetic methods
Steady state levels of 13cRA and serum levels of AT were evaluated from plasma samples collected at baseline and subsequently at each 4-week clinic visit prior to that day's dose. Levels of 13cRA were determined by an isocratic reversed-phase high-performance liquid chromatography (HPLQ method [25] . Levels of AT were determined by a fluorometric micromethod [26] .
Statistical methods
We collected detailed toxicity data from patients' self-report forms, clinical examinations and laboratory studies. The following eight characteristic retinoid-related toxicities were included in this analysis: cheilitis, skin reaction, conjunctivitis, hypertriglyceridemia, increase in aminotransferase, increase in alkaline phosphatase, arthralgia and headache. The current analysis compares only initial-course with final-course toxic effects. We defined 'final course' as the courses) during which the escalating dose of AT reached its highest level. To determine the AT effect on toxicity, we compared the highest toxicity of the initial course with the highest toxicity of the final course. Exact confidence intervals were constructed for estimating the percentages of improvement, no change, and worsening of toxicity. The Wilcoxon signed-rank test determined significance [27] . The original study design called for accrual of 20 patients to detect an assumed reduction from 90% to 45% in rates of major toxicity. This reduction would be detected in this sample size with at least 80% power at 5% significance level.
To assess AT effects on 13cRA serum levels, we measured serum levels of 13cRA and AT during each clinical visit. Our intrapatient dose escalations of AT made it a complex task to interpret changes in serum levels of 13cRA and AT. We accounted for this complexity by plotting the two serum levels against on-study time and prescribed dose levels of each agent. We incorporated all these correlations in determining whether serum levels increased, decreased, fluctuated randomly, or remained unchanged. Intrapatient serum levels of 13cRA can fluctuate randomly (absent AT) [28] . Therefore, we conducted two independent assessments of the AT-dose-to-13cRA-serum-level correlative data. Any discrepancies between these assessments were resolved in discussions among all investigators, who reached a consensus on the effect of AT. In all discrepant cases, we made conservative determinations favoring finding a non-AT-influenced change in serum levels. 
Results
Patient characteristics
A total of 45 patients was accrued. Patient characteristics are presented in Table 1 . Initial eligibility criteria allowed patients with actively progressing disease, however, the criteria were changed to exclude these patients because they often progressed too rapidly to assess effects of escalating AT. Certain cancer-free, high-risk patients were admitted, such as those with oral leukoplakia and postoperative head and neck or non-small cell lung cancer. Median treatment time was four months (range 1-9 months). A total of 223 four-week-long courses were given.
Compliance
Among the total of 45 patients, one patient had progressive disease and died during the first course; one patient refused to participate further after two weeks of treat- ment; another four patients could not be evaluated for compliance because of their inability to swallow the medication and decision not to participate after signing informed consent. The remaining 39 patients had excellent compliance as indicated by taking 5= 90% of the study drugs.
AT effect on 13cRA toxicity
Of the 45 registered patients, 39 could be evaluated for initial-course toxicity. After eight patients dropped out because of disease progression, 31 could be evaluated for final-course toxicity. Only 18% (7/39) of patients in the initial course developed grade 3 or 4 retinoid toxicity (exact 95% confidence interval (CI) of 8%-34%).
We compared initial-course with final-course maximum toxicity grades to assess the effect of increasing AT doses on 13cRA toxicity. One patient had grade 4 toxicity during the initial and final course. Of four patients with grade 3 toxicity in the initial course, one had grade 0, two had grade 2 and one remained at grade 3 toxicity in the final course. Of the twenty patients with grade 2 toxicity in the initial course, the final-course toxicity was grade 2 in six patients, grade 1 in seven and grade 3 in seven patients. The pattern of toxicity change was similar in patients with initial grade 1 toxicity. Rates of increase, decrease and no change in 13cRA toxicity associated with increasing AT doses were similar: 36% decrease (11/31), 32% increase (10/31), 32% did not change (P = 0.84, Wilcoxon signed-rank test). Table 2 reports the mean level (and standard deviation) of serum AT and 13cRA associated with each AT dose level. In 28 patients with complete BcRA serum levels measured over time, 13cRA levels increased in 13 patients (46.4%) and decreased in only two (7.1%). Either variable levels or no change occurred in the other 13 patients (46.4%). AT serum levels did not decrease in any patient.
AT effect on BcRA serum levels
Antitumor response
Of the 21 patients who entered our study with malignant disease that had been unresponsive to previous chemo-therapy, none responded in this trial. Of the total of seven leukoplakia patients, five had complete clinical responses, one had no change and one progressed. Two of these complete responses occurred after four months in leukoplakia patients who had failed to respond to previous therapy of dose-modified 13cRA for 2-3 months (50-100 mg/m 2 /day). The two patients with bronchial neoplasia -one with bronchial metaplasia, one with carcinoma in situ -achieved clinical and histologic complete responses documented by repeat bronchoscopic examinations. The complete response rate in premalignant lesions is 77.8% (7/9) with an exact 95% CI between 40% to 97%.
Discussion
In addition to having established clinical activity, 13cRA frequently causes severe toxicity [1, 2] . Our present clinical trial is the first to prospectively assess whether alphatocopherol (AT) can modify 13cRA toxicity and pharmacokinetics.
We did not detect toxicity differences at different AT dose levels. However, results of our initial course, when compared with other high-dose studies [5] [6] [7] , strongly suggest that AT had a protective effect against 13cRA toxicity. The toxicity of this course (which included 800 IU/day of AT) can be compared very relevantly with toxicity of our previous adjuvant trial of high-dose 13cRA in head and neck cancer [6] . Both were prospective, had comparable daily 13cRA doses (50-100 mg/m 2 and 100 mg/m 2 in the previous and current trials, respectively), and had toxicity criteria and grading determined by virtually the same clinical investigators. Grade ^ 3 (moderate to severe) toxicity rates of the present (initial course) and prior trial were 18% and over 60%, respectively. In the previous trial, patients were randomly assigned to receive either high-dose 13cRA (100 mg/m 2 /day) or placebo. That trial required a protocol dose reduction (from 100 to 50 mg/m 2 /day) because of severe toxicity in the first 44 of the total of 99 patients.
Additional evidence of AT's protective effect comes from another historical comparison. The moderate-tosevere toxicity rate of the present high-dose 13cRA trial was similar to toxicity in our ongoing and prior prospective trials of low-dose 13cRA (in the range of 20 mg/m 2 / day) [9] .
The major limitation of this trial was that it did not prospectively compare 13cRA plus AT with 13cRA alone. Our decision to begin AT immediately was based on ethical considerations of severe toxicity we observed with 13cRA alone at 100 mg/m 2 /day in the adjuvant trial mentioned above [6] .
We believe a better future design would be to conduct a randomized trial of 13cRA alone (plus placebo) versus 13cRA plus AT. Recent data (unavailable prior to the currently reported trial) establishing toxicity and activity of low-dose 13cRA [3, 9] lead us to suggest a 13cRA dose of 25-50 mg/m 2 /day for future study. We suggest an AT dose of 800 IU/day, since this dose was as effective as 2,000 IU/day in our study. Our serial measurements of both 13cRA and AT serum levels during this trial showed that serum levels of 13cRA were not affected by the co-administration of an increasing dose of AT. We also observed that increases in AT plasma levels were less than proportional with increases in AT doses. This phenomenon may largely account for the lack of a difference in 13cRA toxicity between lowest and highest AT doses.
Data of the present trial contribute to a body of preclinical, epidemiologic and other recent clinical data [3, [20] [21] [22] [23] suggesting that AT may enhance 13cRA clinical activity in oral leukoplakia. Our trial produced a complete remission in five of our seven leukoplakia patients, two of which had been resistant to previous high-dose 13cRA alone. The overall complete-response rate in our prior trials of high-dose 13cRA-alone in oral leukoplakia was only 10% [3, 5] .
We believe that results of the present trial justify further study of 13cRA plus AT to define the combination's toxicity profile, clinical efficacy and pharmacokinetics. First, randomized study designed along the lines we suggested above, should be conducted to confirm that AT reduces 13cRA toxicity, while enhancing, or at least maintaining, 13cRA activity. If this is confirmed, large-scale chemoprevention trials of high-dose 13cRA plus AT would be necessary to establish the ultimate clinical efficacy of the regimen in preventing cancer.
